☰

fix

Ryan Morin committed 2026-02-03 08:34:58 -0800 commit cdf1c2872008a59f03fe5b11527479cc64cd6eb4

				pages/clinical.md
			
          @@ -9,7 +9,7 @@ link-citations: true

           ## Therapeutic targets

           |Gene|Status|Entity|Therapy|Biomarker?|

          -|-|-|-|-|

          +|-|-|-|-|-|

           |[BCL2](/BCL2)|not approved|DLBCL|venetoclax|Not applicable|

           |[BTK](/BTK#clinical-relevance)|not approved|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|

           |[CD79B](/CD79B#clinical-relevance)|FDA approved|DLBCL|polatuzumab vedotin|ABC gene expression signature|

...	...	@@ -9,7 +9,7 @@ link-citations: true
9	9	## Therapeutic targets
10	10
11	11	\|Gene\|Status\|Entity\|Therapy\|Biomarker?\|
12		-\|-\|-\|-\|-\|
	12	+\|-\|-\|-\|-\|-\|
13	13	\|[BCL2](/BCL2)\|not approved\|DLBCL\|venetoclax\|Not applicable\|
14	14	\|[BTK](/BTK#clinical-relevance)\|not approved\|DLBCL\|ibrutinib\|ABC gene expression signature, MCD genetic subgroup\|
15	15	\|[CD79B](/CD79B#clinical-relevance)\|FDA approved\|DLBCL\|polatuzumab vedotin\|ABC gene expression signature\|